Todd Harris - Mar 24, 2023 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Chief Executive Officer, Director
Signature
/s/ Ali D. Fawaz, Attorney-in-Fact
Stock symbol
TYRA
Transactions as of
Mar 24, 2023
Transactions value $
-$81,290
Form type
4
Date filed
3/28/2023, 07:09 PM
Previous filing
Mar 23, 2023
Next filing
Mar 31, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Options Exercise $383 +170 +0.01% $2.25* 1.7M Mar 24, 2023 Direct
transaction TYRA Common Stock Sale -$2.72K -170 -0.01% $16.00 1.7M Mar 24, 2023 Direct F1
transaction TYRA Common Stock Options Exercise $6.67K +2.96K +0.17% $2.25* 1.7M Mar 27, 2023 Direct
transaction TYRA Common Stock Sale -$47.4K -2.96K -0.17% $16.00 1.7M Mar 27, 2023 Direct F1
transaction TYRA Common Stock Options Exercise $6.25K +2.78K +0.16% $2.25* 1.7M Mar 28, 2023 Direct
transaction TYRA Common Stock Sale -$44.5K -2.78K -0.16% $16.00 1.7M Mar 28, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -170 -0.04% $0.00 410K Mar 24, 2023 Common Stock 170 $2.25 Direct F2
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -2.96K -0.72% $0.00 407K Mar 27, 2023 Common Stock 2.96K $2.25 Direct F2
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -2.78K -0.68% $0.00 404K Mar 28, 2023 Common Stock 2.78K $2.25 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022.
F2 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.